Dr. Arvind Kumar Gupta
(M.Pharm, PDCR, PGDMM & Ph.D)
GATE 2003 Qualified with 97.2 percentile
Dr. S. N. Dev College of Pharmacy
Shamli (U.P.)

OFFICE:
BUILDING No. 3/314, OFFICE-1, GAUSHALA ROAD, SHAMLI DISTRICT SHAMLI (U.P.) – 247776
Mobile: +91-9719638415
Email: arvindrkgit@gmail.com, www.phbeducation.com

Course Name	**: D. Pharm**
Year	**: Second Year**
Subject Name	**: Hospital & Clinical Pharmacy**
Topic Name	**: Radiopharmaceuticals**

Ch – 6

Radiopharmaceuticals

Radiopharmaceuticals are a specialized category of medicinal formulations containing radioisotopes, used in nuclear medicine for diagnosis and therapy. They combine a radioactive component with a pharmaceutical agent that targets specific tissues, organs, or cellular receptors.

Types of Radiopharmaceuticals

1. Diagnostic Radiopharmaceuticals:

- **Purpose:** Used for imaging and functional studies of organs and tissues.
- **Common Isotopes:** Technetium-99m (Tc-99m), Fluorine-18 (F-18), Iodine-123 (I-123).
- **Imaging Techniques:** Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET).

2. Therapeutic Radiopharmaceuticals:

- **Purpose:** Used to treat various medical conditions, such as cancer and hyperthyroidism, by delivering targeted radiation.
- **Common Isotopes:** Iodine-131 (I-131), Yttrium-90 (Y-90), Lutetium-177 (Lu-177).
- **Therapeutic Uses:** Treatment of thyroid cancer, neuroendocrine tumors, and certain types of lymphoma.

Preparation and Handling of Radiopharmaceuticals

1. **Regulatory Compliance:**

- **Licensing:** Production and use are strictly regulated by national and international bodies such as the U.S. Nuclear Regulatory Commission (NRC), the Food and Drug Administration (FDA), and the International Atomic Energy Agency (IAEA).
- **Standards:** Must comply with Good Manufacturing Practices (GMP) and radiological safety standards.

2. **Production:**

- **Cyclotrons and Reactors:** Radioisotopes are produced in cyclotrons or nuclear reactors.
- **Radiopharmacy:** Specialized facilities where radiopharmaceuticals are compounded. These facilities must have proper shielding, ventilation, and contamination control measures.
- **Radiochemical Purity:** Ensuring high radiochemical purity is critical to prevent unwanted radiation exposure and ensure effective targeting.

3. **Aseptic Techniques:**

- **Sterility:** Many radiopharmaceuticals, especially those used for injection, must be sterile and pyrogen-free.

- **Cleanroom Environment:** Preparation occurs in a cleanroom environment with laminar airflow hoods to maintain sterility.

4. **Quality Control:**
   - **Testing:** Includes checks for radiochemical purity, pH, sterility, endotoxins, and specific activity.
   - **Documentation:** Detailed records of production, quality control results, and patient-specific dosing must be maintained.

Administration and Safety

1. **Administration:**
   - **Routes:** Common routes include intravenous injection, oral administration, and inhalation.
   - **Dosage:** Carefully calculated based on patient-specific factors, including body weight, organ function, and the purpose of the study or treatment.
   - **Imaging Protocols:** For diagnostic use, specific imaging protocols must be followed to optimize image quality and diagnostic accuracy.
2. **Radiation Safety:**
   - **Protective Measures:** Healthcare providers must use protective equipment such as lead aprons, shields, and gloves to minimize radiation exposure.
   - **Patient Instructions:** Patients may need to follow specific instructions to minimize radiation exposure to others, such as avoiding close contact with others for a certain period after administration.
   - **Waste Disposal:** Radioactive waste must be handled and disposed of according to regulatory guidelines to prevent environmental contamination.
3. **Monitoring and Follow-Up:**
   - **Post-Administration Monitoring:** Patients receiving therapeutic radiopharmaceuticals require close monitoring for therapeutic effectiveness and potential side effects.
   - **Imaging and Assessment:** For diagnostic radiopharmaceuticals, follow-up imaging is essential to interpret the results accurately and make clinical decisions.

Common Radiopharmaceuticals and Their Uses

1. Diagnostic Radiopharmaceuticals:
   - **Technetium-99m (Tc-99m):** Widely used in SPECT imaging for bone scans, cardiac perfusion studies, and renal imaging.
   - **Fluorine-18 (F-18) FDG:** Used in PET imaging to assess metabolic activity in oncology, neurology, and cardiology.

2. Therapeutic Radiopharmaceuticals:
   - **Iodine-131 (I-131):** Used for the treatment of thyroid cancer and hyperthyroidism.
   - **Yttrium-90 (Y-90):** Used in radioembolization for liver cancer and in the

treatment of certain lymphomas.

- **Lutetium-177 (Lu-177) DOTATATE:** Used for treating neuroendocrine tumors.

6.1	Storage, dispensing and disposal of radiopharmaceuticals

Storage

1. **Facilities and Equipment:**
   - **Shielded Storage Areas:** Radiopharmaceuticals must be stored in shielded environments, such as lead-lined cabinets or refrigerators, to minimize radiation exposure to personnel and the environment.
   - **Controlled Temperature:** Storage conditions should comply with the manufacturer's recommendations, often requiring refrigeration or room temperature control.
   - **Segregation:** Different types of radiopharmaceuticals should be segregated to prevent cross-contamination. This includes separating therapeutic radiopharmaceuticals from diagnostic ones.
2. **Security and Access Control:**
   - **Restricted Access:** Storage areas should be secure and accessible only to authorized personnel to prevent unauthorized use or theft.
   - **Inventory Management:** A strict inventory management system should be in place to track the quantities, lot numbers, and expiration dates of all radiopharmaceuticals.
3. **Radiation Safety:**
   - **Monitoring:** Regular monitoring of radiation levels in storage areas to ensure they are within safe limits.
   - **Signage:** Appropriate warning signs and radiation hazard symbols should be displayed prominently.

Dispensing

1. **Preparation Environment:**
   - **Aseptic Technique:** Dispensing must be performed using aseptic techniques in a cleanroom environment with laminar airflow hoods to ensure sterility, particularly for injectable radiopharmaceuticals.
   - **Shielding:** Use of shielding tools like lead glass shields, syringe shields, and tongs to minimize radiation exposure during dispensing.
2. **Dosing and Calibration:**
   - **Dose Calculation:** Accurate calculation of doses based on patient-specific parameters, such as weight, organ function, and treatment protocols.

- **Calibration:** Use of dose calibrators to measure and verify the radioactivity of dispensed doses.

3. **Labeling:**
   - **Detailed Labels:** Each dispensed dose must be labeled with patient information, radioisotope, activity, time of calibration, expiration time, and handling precautions.
   - **Color Coding:** Use of color-coded labels to distinguish between different types of radiopharmaceuticals.
4. **Transport:**
   - **Shielded Containers:** Use of shielded transport containers to safely move radiopharmaceuticals within the facility and to the administration site.
   - **Documentation:** Comprehensive documentation of the transfer process, including sign-off by receiving personnel.

Disposal

1. **Regulatory Compliance:**
   - **Adherence to Regulations:** Disposal must comply with national and international regulations, such as those from the Nuclear Regulatory Commission (NRC) and Environmental Protection Agency (EPA) in the United States, or equivalent bodies in other countries.
   - **Documentation:** Detailed records of the disposal process, including the type of radiopharmaceutical, activity level, date of disposal, and method used.
2. **Decay-in-Storage:**
   - **Decay Storage Facilities:** Radioactive waste with short half-lives can be stored in designated decay-in-storage areas until their radioactivity has decayed to safe levels, after which they can be disposed of as non-radioactive waste.
   - **Monitoring:** Regular monitoring to determine when the waste has decayed sufficiently for safe disposal.
3. **Waste Segregation and Packaging:**
   - **Segregation:** Different types of radioactive waste (e.g., solid, liquid, sharps) must be segregated to ensure appropriate disposal methods.
   - **Packaging:** Use of appropriate containers designed to safely contain radioactive waste and prevent leakage or contamination.
4. **Disposal Methods:**
   - **Incineration:** Some radioactive waste, particularly contaminated biological materials, may be incinerated in specialized facilities.
   - **Landfill:** Solid waste that has decayed to safe levels can be disposed of in designated landfills following regulatory guidelines.
   - **Return to Supplier:** In some cases, unused or expired radiopharmaceuticals can be returned to the supplier for disposal.

5. **Environmental and Safety Monitoring:**
    - **Radiation Monitoring:** Continuous monitoring of radiation levels in disposal and storage areas to ensure safety.
    - **Environmental Impact:** Regular assessment of the environmental impact of disposal practices to ensure compliance with environmental protection standards.